SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-179631
Filing Date
2023-06-30
Accepted
2023-06-30 09:03:58
Documents
14
Period of Report
2023-06-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d442654d8k.htm   iXBRL 8-K 25084
2 EX-99.1 d442654dex991.htm EX-99.1 19282
6 GRAPHIC g442654snap1.jpg GRAPHIC 4445
  Complete submission text file 0001193125-23-179631.txt   180352

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alny-20230630.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20230630_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20230630_pre.xml EX-101.PRE 11261
8 EXTRACTED XBRL INSTANCE DOCUMENT d442654d8k_htm.xml XML 3433
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 231059740
SIC: 2834 Pharmaceutical Preparations